

University of Groningen

Sodium and potassium intake as determinants of cardiovascular and renal health

Kieneker, Lyanne Marriët

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Kieneker, L. M. (2019). *Sodium and potassium intake as determinants of cardiovascular and renal health*. [Groningen]: Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

LIST OF PUBLICATIONS



L.M. Kieneker, R.T. Gansevoort, K.J. Mukamal, R.A. de Boer, G. Navis, S.J.L. Bakker, M.M. Joosten. Urinary potassium excretion and risk of developing hypertension: The Prevention of Renal and Vascular End-stage Disease study. *Hypertension*. 2014;64:769-776.

L.M. Kieneker, R.T. Gansevoort, R.A. de Boer, F.P. Brouwers, E.J.M. Feskens, J.M. Geleijnse, G. Navis, S.J.L. Bakker, M.M. Joosten. Urinary potassium excretion and risk of cardiovascular events. *Am J Clin Nutr*. 2016;103(5):1204-1212.

L.M. Kieneker, S.J.L. Bakker, R.A. de Boer, G. Navis, R.T. Gansevoort, M.M. Joosten. Low potassium excretion but not high sodium excretion is associated with increased risk of developing chronic kidney disease. *Kidney Int*. 2016 Oct;90(4):888-96.

M.F. Eisenga, **L.M. Kieneker**, S.S. Soedamah-Muthu, E. van den Berg, P.E. Deetman, G. Navis, R.O.B. Gans, C.A.J.M. Gaillard, S.J.L. Bakker, M.M. Joosten. Urinary potassium excretion, renal ammoniogenesis and risk of graft failure and mortality in renal transplant recipients. *Am J Clin Nutr*. 2016 Dec;104(6):1703-1711.

J.M. Taylor, **L.M. Kieneker**, M.H. de Borst, S.T. Visser, I.P. Kema, S.J.L. Bakker, R.T. Gansevoort. Urinary calcium excretion and risk of chronic kidney disease in the general population. *Kidney Int Rep*. 2016 May; 3(2):366-379.

A. Abbasi, **L.M. Kieneker**, E. Corpeleijn, R.T. Gansevoort, R.A. de Boer, R.O.B. Gans, J. Struck, H.L. Hillege, R.P. Stolk, G. Navis, S.J.L. Bakker. Plasma N-terminal pro-somatostatin and incident cardiovascular disease and all-cause mortality in the general population. *Clin Chem*. 2017 Jan;63(1):278-287.

L.M. Kieneker, M.F. Eisenga, M.M. Joosten, R.A. de Boer, R.T. Gansevoort, J.E. Kootstra, G. Navis, S.J.L. Bakker. Plasma potassium, diuretic use and risk of developing chronic kidney disease in a predominantly White population. *PLoS One*. 2017 Mar 27;12(3):e0174686.

S.K. Kunutsor, **L.M. Kieneker**, S.J.L. Bakker, R.W. James, R.P.F. Dullaart. Incident type 2 diabetes is associated with HDL, but not with its anti-oxidant constituent - paraoxonase-1: The prospective cohort PREVEND study. *Metabolism*. 2017 Aug;73:43-51.

S.K. Kunutsor, **L.M. Kieneker**, S.J.L. Bakker, R.W. James, R.P.F. Dullaart. The inverse association of HDL-cholesterol with future risk of hypertension is not modified by its antioxidant constituent, paraoxonase-1: The PREVEND prospective cohort study. *Atherosclerosis*. 2017 Aug;263:219-226.

L.M. Kieneker, O. Hartmann, J. Struck, A. Bergmann, R.T. Gansevoort, M.M. Joosten, E. van den Berg, R.A. de Boer, S.J.L. Bakker. Plasma proenkephalin and poor long-term outcome in renal transplant recipients. *Transplant Direct*. 2017 Jul 7;3(8):e190.

S.K. Kunutsor, **L.M. Kieneker**, S. Burgess, S.J.L. Bakker, R. P.F. Dullaart. Circulating Total Bilirubin and Future Risk of Hypertension in the General Population: the PREVEND Prospective Study and a Mendelian Randomization Approach. *J Am Heart Assoc*. 2017 Nov;13;6(11).

M.F. Eisenga, **L.M. Kieneker**, D.J. Touw, P. van der Meer, G. Huls, C.A.J.M. Gaillard, S.J.L. Bakker. Active Smoking, Hematocrit and Fasting Circulating Erythropoietin Concentrations in the General Population. *Mayo Clinic Proceedings*. 2018 Mar;93(3):337-343.

W.C. Meijers, M. Maglione, S.J.L. Bakker, R. Oberhuber, **L.M. Kieneker**, S. de Jong, W.B. Nagengast, A.R. Lyon, B. van der Vegt, D.J. van Veldhuisen, D. Westenbrink, P. van der Meer, H.H.W. Sillje, R.A. de Boer. The failing heart stimulates tumor growth by circulating factors. *Circulation*. 2018 Aug 14;138(7):678-691.

S.K. Kunutsor, J.M. Spee, **L.M. Kieneker**, R.T. Gansevoort, Robin P.F. Dullaart, A.J. Voerman, D.J. Touw, S.J.L. Bakker. Self-Reported Smoking, Urine Cotinine, and Risk of Cardiovascular Disease: Findings from the PREVEND Prospective Cohort Study. *J Am Heart Assoc*. 2018 May 2;7(10).

S.K. Kunutsor, J.L. Flores-Guerrero, **L.M. Kieneker**, T. Nilsen, C. Hidden, E. Sundrehagen, S. Seidu, R.P.F. Dullaart, S.J.L. Bakker. Plasma calprotectin and risk of cardiovascular disease: findings from the PREVEND prospective cohort study. *Atherosclerosis*. 2018 Jun 15;275:205-213.

L.M. Kieneker, J. Struck, R.T. Gansevoort, M. M. Joosten, R. A. de Boer, O. Hartmann, A. Bergmann, S.J.L. Bakker. Proenkephalin and risk of developing chronic kidney disease: the Prevention of Renal and Vascular End-stage Disease study. *Biomarkers*. 2018 Jul;23(5):474-482.

R. El Boustany, I. Tasevska, E. Meijer, **L.M. Kieneker**, G. Lefèvre, R. Roussel, O. Melander, R.T. Gansevoort, G. Velho. Plasma copeptin, a surrogate of vasopressin, and chronic kidney disease in 3 European cohorts from the general population. *JCI Insight*. 2018;3(13).

S.K. Kunutsor, J.L. Flores Guerrero, **L.M. Kieneker**, T. Nilsen, E. Sundrehagen, S. Seidu, R.P.F. Dullaart, S.J.L. Bakker. Plasma Neutrophil Gelatinase-Associated Lipocalin and Risk of Cardiovascular Disease: Findings from the PREVEND Prospective Cohort Study. *Clin Chim Acta*. 2018 Jul 20;486:66-75.

L.M. Kieneker, M.F. Eisenga, M.M. Joosten, R.A. de Boer, R.T. Gansevoort, G. Navis, S.J.L. Bakker. Urinary sodium excretion and risk of stroke. *Mayo Clin Proc.* 2018; 93(12): 1803-1809.

J.L. Flores-Guerrero, M.C.J. Osté, **L.M. Kieneker**, E.G. Gruppen, J.D. Otvos, M.A. Connelly, R.P.F. Dullaart, S.J.L. Bakker. Plasma Branched-Chain Amino Acids and Risk of Incident Type 2 Diabetes: Results from the PREVEND Prospective Cohort Study. *J Clin Med.* 2018: Dec 4;7(12).

C.H.L. Thio, P. Vart, **L.M. Kieneker**, H. Snieder, R.T. Gansevoort, U. Bültmann. Educational level and risk of chronic kidney disease: longitudinal data from the PREVEND Study. *NDT.* 2018, *in press.*

M.F. Eisenga, H.J.C.M. Wouters, **L.M. Kieneker**, M. van der Klauw, P. van der Meer, B.H.R. Wolffenbuttel, C.A.J.M. Gaillard, J. Kootstra-Ros, D.J. Touw, G. Huls, and S.J.L. Bakker. Active smoking and Macrocytosis in the General Population: Two Population-based Cohort Studies. *Am J Hematol.* 2018, *in press.*

L.M. Kieneker, M.F. Eisenga, S.J.L. Bakker. In Reply – ‘Low-sodium Intake: a Risk Factor for Stroke?’. *Mayo Clin Proc.* 2018, *in press.*

J.L. Flores-Guerrero, M.A. Connelly, I. Shalaurova, E.G. Gruppen, **L.M. Kieneker**, R.P.F. Dullaart, S.J.L. Bakker. Lipoprotein Insulin Resistance Index, a High-Throughput Measure of Insulin Resistance, is Associated with Incident Type 2 Diabetes Mellitus in the PREVEND Study. *J Clin Lipidol.* 2018, *in press.*